BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 560 filers reported holding BIO-TECHNE CORP in Q2 2024. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $948,288 | +1.8% | 13,235 | 0.0% | 0.55% | +4.8% |
| Q1 2024 | $931,612 | -9.5% | 13,235 | -0.7% | 0.52% | -15.8% |
| Q4 2023 | $1,028,929 | +35.7% | 13,335 | +19.8% | 0.62% | +14.2% |
| Q3 2023 | $757,959 | -15.3% | 11,135 | +1.6% | 0.54% | -9.1% |
| Q2 2023 | $894,665 | +10.0% | 10,960 | 0.0% | 0.60% | -0.2% |
| Q1 2023 | $813,122 | -10.5% | 10,960 | 0.0% | 0.60% | -20.1% |
| Q4 2022 | $908,365 | +16.8% | 10,960 | +300.0% | 0.75% | +2.5% |
| Q3 2022 | $778,000 | -16.9% | 2,740 | +1.5% | 0.73% | -20.1% |
| Q2 2022 | $936,000 | -9.9% | 2,700 | +12.5% | 0.91% | +16.8% |
| Q1 2022 | $1,039,000 | -16.3% | 2,400 | 0.0% | 0.78% | -7.4% |
| Q4 2021 | $1,242,000 | +6.8% | 2,400 | 0.0% | 0.84% | +8.1% |
| Q3 2021 | $1,163,000 | +7.6% | 2,400 | 0.0% | 0.78% | +5.4% |
| Q2 2021 | $1,081,000 | +17.9% | 2,400 | 0.0% | 0.74% | +7.9% |
| Q1 2021 | $917,000 | +20.3% | 2,400 | 0.0% | 0.69% | +15.7% |
| Q4 2020 | $762,000 | – | 2,400 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
| Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
| Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
| Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
| Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
| STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
| DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
| MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
| Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
| Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |